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Objectives We sought to investigate the clinical-genetic profile of left-dominant arrhythmogenic cardiomyopathy (LDAC).
Background In the absence of coronary disease and left ventricular (LV) systolic dysfunction, lateral T-wave inversion and ar-
rhythmia of LV origin are often considered benign. Similarly, chest pain with enzyme release might be attributed
to viral myocarditis. We hypothesized that these abnormalities might be manifestations of the “left-dominant”
subtype of arrhythmogenic right ventricular cardiomyopathy.
Methods The 42-patient cohort was established through clinical evaluation of individuals with unexplained (infero)lateral
T-wave inversion, arrhythmia of LV origin, and/or proven LDAC/idiopathic myocardial fibrosis in the family.
Results Patients presented from adolescence to age 80 years with arrhythmia or chest pain but not heart failure.
Desmosomal mutations were identified in 8 of 24 families (15 of 33 patients). Magnetic resonance findings
included LV late-enhancement in a subepicardial/midwall distribution, corresponding to fibrofatty replacement
and fibrosis on histopathology. Fifty percent had previously been misdiagnosed with viral myocarditis, dilated
cardiomyopathy (DCM), hypertrophic cardiomyopathy, or idiopathic ventricular tachycardia. Arrhythmic events
included presentation with ventricular fibrillatory arrest in 1 patient and 2 instances of sudden cardiac death
during follow-up.
Conclusions Arrhythmogenic cardiomyopathy is distinguished from DCM by a propensity towards arrhythmia exceeding the
degree of ventricular dysfunction. The left-dominant subtype is under-recognized owing to misattribution to other
disorders and lack of specific diagnostic criteria. Clinicians are alerted to the possibility of LDAC in patients of
any age with unexplained arrhythmia of LV origin, (infero)lateral T-wave inversion, apparent DCM (with arrhyth-
mic presentation), or myocarditis (chest pain and enzyme rise with unobstructed coronary arteries). (J Am Coll
Cardiol 2008;52:2175–87) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.019s
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meft-dominant arrhythmogenic cardiomyopathy (LDAC) is
haracterized pathologically by fibroadipose replacement of
he left ventricle (LV), often occurring as a circumferential
and in the outer one-third of the myocardium and the
ight side of the interventricular septum (1–4). First de-
cribed at post-mortem examination in sudden cardiac
eath (SCD) victims, LDAC has been observed in vivo in
rom the *Inherited Cardiovascular Disease Group, The Heart Hospital, London,
nited Kingdom; †Department of Histopathology, Royal Free and University
ollege Medical School, University College London, London, United Kingdom;
Cardiovascular Magnetic Resonance Unit, National Heart & Lung Institute,
ondon, United Kingdom; and the §Wolfson Foundation Medical Image Comput-
ng Laboratory, Imperial College, London, United Kingdom. This work was
upported by the British Heart Foundation (to Drs. Sen-Chowdhry, Syrris, Ward,
nd McKenna), CORDA (to Drs. Pennell and Prasad), and the European Commis-c
ion 5th Framework Program (ARVC/D project, QLG1-CT-2000-01091).
Manuscript received July 23, 2008, accepted September 4, 2008.urviving relatives, patients with ventricular tachycardia
VT) of LV origin, and families with desmoplakin muta-
ions (5–9).
See page 2188
More recently, LDAC has been recognized as 1 of 3
atterns of disease expression among families with arrhyth-
ogenic right ventricular cardiomyopathy (ARVC) (10). In
ontrast to the “classic” subtype, with its well-known pre-
ilection for the right ventricle, and the “biventricular”
ariant, defined by parallel involvement of both ventricles,
DAC is characterized by early and predominant LV
nvolvement (10). Salient features include inverted T waves
n the lateral and/or inferior leads and ventricular arrhyth-
ia of right bundle branch block (RBBB) morphology,
onsistent with LV origin (1,5–7,10). In everyday clinical
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87practice, these abnormalities are
often considered benign in the
absence of obstructive coronary
artery disease and LV systolic
dysfunction.
Less well-defined is the entity
known as idiopathic myocardial
fibrosis (IMF), which accounts
for 1% to 3% of cases of SCD
(11–13). Idiopathic myocardial
fibrosis is characterized by hetero-
geneous interstitial fibrosis with
a predilection for the inferior LV
wall (13). Replacement fibrosis is
also observed; however, coronary
artery disease and other struc-
tural abnormalities are by defini-
tion absent, indicating a repair
process for which the primary
insult is unknown. While infec-
tive myocarditis and age-related
degeneration have been cited as
possible causes, it has also been
suggested that IMF might be
part of the same disease spectrum
as ARVC. The clinical counter-
part of IMF remains incom-
pletely understood.
Although the relative paucity
of clinical reports of LDAC and
IMF is anecdotally attributed to
their low prevalence, under-
recognition might be a factor.
We sought to define the clinical
and genetic profile of LDAC/
IMF and facilitate incorporation
of its features into forthcoming
revisions of the task force diag-
nostic criteria for ARVC.
Methods
The Heart Hospital is a tertiary
enter with a dedicated Inherited Cardiovascular Disease
ervice. Standard referrals include index cases with estab-
ished or suspected hypertrophic cardiomyopathy (HCM),
ilated cardiomyopathy (DCM), or ARVC and relatives
equiring prospective assessment for familial cardiomyopa-
hy or sudden unexplained death syndrome. All patients are
valuated de novo to provide independent diagnosis and
lan management strategies.
The study protocol is outlined in Table 1 (14–18),
ncluding inclusion/exclusion criteria at each stage and
etails of clinical work-up and genetic studies. During stage
, we identified a series of patients with arrhythmia of LV
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
CI  confidence interval
CMR  cardiovascular
magnetic resonance
DCM  dilated
cardiomyopathy
ECG  electrocardiogram
HCM  hypertrophic
cardiomyopathy
IMF  idiopathic
myocardial fibrosis
LBBB  left bundle branch
block
LDAC  left-dominant
arrhythmogenic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVNC  left ventricular
noncompaction
PVC  premature
ventricular complex
RBBB  right bundle
branch block
RV  right ventricle/
ventricular
SCD  sudden cardiac
death
VT  ventricular
tachycardia
WMA  wall motion
abnormalityrigin or (infero)lateral T-wave inversion in whom re- assessment failed to confirm the referring diagnosis. These
ndividuals were entered into the study on the basis of
nexplained ventricular arrhythmia of RBBB morphology
nd/or inverted T waves in the LV leads. Individuals with
roven LDAC/IMF in the family comprised the remainder
f the initial study population. In stage 2, probands with
tructural features of arrhythmogenic cardiomyopathy and
elatives with left-sided features (viz., arrhythmia of LV
rigin, inverted T waves confined to the [infero]lateral
eads, predominant LV dilation/dysfunction, or marked late
adolinium enhancement [LGE] in the LV with preserved
ight ventricular [RV] function) were entered into the final
DAC cohort to allow proposal and validation of clinical
iagnostic criteria.
tatistical analysis. Data were tested for normality with
he Shapiro-Wilk test. The Spearman and Pearson corre-
ation coefficients were calculated as appropriate. Two-tailed
values are cited to 4 decimal places. Key percentages are
rovided with 95% confidence intervals (CIs).
esults
nitial study population. The initial study population
omprised 73 individuals from 29 different families. During
he 4-year study period, only 2 patients were referred for
valuation of VT of presumed LV origin with cause un-
nown. A further 17 patients had been referred with
ifficult-to-manage arrhythmia or challenging risk stratifi-
ation issues in the setting of a presumed diagnosis of DCM
n  12), HCM (n  3), mitral valve prolapse (n  1), or
yocarditis/left ventricular noncompaction (LVNC) (n  1).
he patients with presumed HCM did not fulfill the
iagnostic criteria thereof. The diagnosis was queried in the
atients with presumed DCM owing to presentation with
ymptoms of arrhythmia, historic and contemporary ab-
ence of clinical heart failure, and burden of ventricular
rrhythmia out of proportion to the often mild degree of LV
ilation/dysfunction. At initial review, all 19 patients were
onsidered to have otherwise unexplained arrhythmia of LV
rigin and/or (infero)lateral T-wave inversion and were
ntered into the study on this basis. In 6 patients, the
ndication for referral was a family history of DCM (n 3),
RVC (n  2), or sudden unexplained death syndrome
n  1), but enrollment into the LDAC study was based on
dentification of unexplained arrhythmia of LV origin
nd/or inverted T waves in the LV leads. The remaining 48
atients were recruited on the basis of proven LDAC (n 
3) or IMF (n  5) in the family; of these, 4 had previously
resented to local centers and been diagnosed with myocar-
itis/idiopathic VT (n  2) or benign ventricular ectopy
n  2).
DAC cohort. Twenty subjects with a family history of
DAC/IMF had no abnormalities on clinical evaluation
nd were not eligible for stage 2. A further 11 individuals
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December 16/23, 2008:2175–87 Left-Dominant Arrhythmogenic Cardiomyopathyrom 5 different families had evidence of arrhythmogenic
ardiomyopathy but demonstrated “classic” RV or “biven-
ricular” disease expression and were excluded from the
DAC cohort owing to a lack of “left-dominant” features.
he remaining 42 patients were entered into the final
tudy Protocol
Table 1 Study Protocol
Stage 1
Inclusion criteria
One or more of the following:
● Ventricular arrhythmia of RBBB morphology
● Isolated (infero)lateral T-wave inversion
● Proven LDAC/IMF in the family
Exclusion criteria
Any of the following:
● Systemic arterial hypertension (160/100 mm Hg documented and confirm
● Coronary artery disease (obstruction 50% of the luminal diameter in a maj
● Hypertrophic cardiomyopathy
● Previous or current clinical heart failure
● Inducible ischemia on stress test
● History of chronic excess of alcohol consumption
● Sustained, rapid, uncontrolled supraventricular arrhythmia
● Systemic diseases
● Pericardial diseases
● Congenital heart disease
● Cor pulmonale
Stage 2: inclusion criteria
For subjects entered on the basis of ventricular arrhythmia of RBBB morphology o
● Evidence of structural LV disease (dilation, systolic impairment, unequivocal WM
For subjects entered on the basis of a family history of LDAC/IMF:
● Ventricular arrhythmia of RBBB morphology, isolated (infero)lateral T-wave inve
exceeding that of the RV; extensive LGE with preserved RV function)
Clinical evaluation
12-lead ECG
Signal-averaged ECG with a 40-Hz filter
2D echocardiography
Ambulatory ECG monitoring
Exercise testing  metabolic gas exchange measurements (15)
CMR with protocol and consensus 2-reader review (D.J.P., W.J.M., S.S.C., S.K.P.)
Mutation screening of 5 desmosomal genes (plakoglobin, desmoplakin, plakophil
(Endomyocardial biopsy taken from right side of interventricular septum at setting
Arrhythmia grading scale
0 Nil of significance or supraventricular arrhythmia only
1 4 PVCs on exercise testing or 200 PVCs on 24-h Holter monitoring but in
2 200 PVCs/24 h on Holter or 4 PVCs on exercise testing or rare isolated
3 400 PVCs/24 h on Holter or isolated NSVT on 2 or more tapes within 6 m
4 1000 PVCs/24 h on Holter or NSVT in the context of frequent PVCs
5 Recurrent NSVT with rate 200 beats/min and/or 6 consecutive beats ac
6 Sustained VT
CMR analysis
CMR-derived EDVs expressed as a percentage of predicted throughout to adjust fo
Extent of LGE in the LV (LV lesion) was visually graded on a 5-point ordinal scale:
0  nil;
1  mild, affecting 2 segments;
2  mild to moderate, affecting 3 segments;
3  moderate to severe, affecting 4 segments;
4  severe, affecting 5 or more segments
ee references 14–18.
2D  2-dimensional; BSA  body surface area; CMR  cardiovascular magnetic resonance;
eft-dominant arrhythmogenic cardiomyopathy; LGE  late gadolinium enhancement; LV  left ve
ight bundle branch block; RV  right ventricular; VT  ventricular tachycardia; WMA  wall motiDAC cohort. cemographic data, electrocardiography, and arrhythmic
ndings. Baseline clinical characteristics of the LDAC
ohort are presented in Table 2. Of 29 patients aged 40
ears, 19 (66%) had previously undergone cardiac catheter-
zation, which showed unobstructed coronary arteries in all
epeated measurements and/or evidence of target-organ disease)
ch)
ted (infero)lateral T-wave inversion:
LGE)
r evidence of structural left-dominant disease (LV dilation/systolic impairment
viously described (14)
esmoglein-2, and desmocollin-2) by direct sequencing
vice implantation)
g couplets and/or bigeminy
ith rate 200 beats/min and/or 6 consecutive beats
or frequent ectopy and NSVT on exercise testing
nied by frequent PVCs
al variations related to age, gender, and BSA (14,17,18)
electrocardiogram; EDV  end-diastolic volume; IMF  idiopathic myocardial fibrosis; LDAC 
r; NSVT  nonsustained ventricular tachycardia; PVC  premature ventricular complex; RBBB 
rmality.ed at r
or bran
r isola
A, or
rsion, o
as pre
in-2, d
of de
cludin
NSVT w
onths
compa
r norm
ECG ases. Three of these patients had been hospitalized with
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87cute chest pain, associated in 2 with troponin rise. The
emainder achieved a good workload on exercise testing
ithout chest pain or ST-segment changes (Duke treadmill
core 5). None reported orthopnea, paroxysmal nocturnal
yspnea, or ankle swelling; physical signs of heart failure
ere absent.
Serial electrocardiograms (ECGs) obtained over 5 years
ere available in 3 individuals. Two had T-wave flattening/
nversion in V5 to V6 on initial evaluation. This gradually
xtended to V4, V3, V2, and the inferior leads during
ollow-up. In 1 of these patients, the evolution of repolar-
zation abnormalities in the right precordial leads coincided
ith the appearance of prominent aneurysmal changes in
he free wall of the RV on annual cardiovascular magnetic
esonance (CMR) examinations. A third patient showed
radual anti-clockwise rotation from a normal QRS axis to
eft axis deviation.
tructural abnormalities. Imaging results are summarized
n Table 2. By CMR, 7 patients had left ventricular
ontinued
Table 2 Continued
Documented ventricular arrhythmia (of
LV or biventricular origin)‡
Grade
0 8 (19%)
1 0
2 6 (14%)
3 6 (14%)
4 16 (38%)
5 5 (12%)
6 1 (2%)
Tissue characterization by CMR†§
Late enhancement in LV 40/40 (100%; 95% CI 89%–100%)
Pattern
Subepicardial 12 (30%)
Mid-wall 5 (12.5%)
Both 23 (57.5%)
Extent
Grade I (mild) 8 (20%)
Grade II (mild to moderate) 6 (15%)
Grade III (moderate to severe) 7 (17.5%)
Grade IV (severe) 19 (47.5%)
Location
Septum 22 (55%; 95% CI 39%–70%)
Inferior wall 32 (80%)
Inferolateral wall 37 (92.5%)
Anterolateral wall 20 (50%)
Anterior wall 8 (20%)
 42. *One patient presented with ventricular fibrillation (VF) arrest. †CMR was performed in 41
f 42 patients. The exception died suddenly at her local hospital while awaiting inpatient transfer
or further investigations. One boy did not receive gadolinium-diethyltriaminepentaacetic acid due
o age and weight stipulations. ‡Thirty-four patients (81%) had ventricular arrhythmia of grade2.
entricular extrasystoles were recorded in sufficient leads, predominantly during exercise testing,
o permit analysis of morphology in 33. Of these, 15 (45%) had ventricular arrhythmia of RBBB
orphology only, consistent with LV origin. The remaining 18 (55%) had PVCs of both RBBB and left
undle branch block configuration. §The prevalence of RV late enhancement is not cited, owing to
he difficulty of distinguishing this feature frommyocardial fat, compounded by setting of inversion
imes to null the LV myocardium and the absence of a fat-suppressed inversion recovery sequence.
EF  ejection fraction; SAECG  signal-averaged electrocardiogram; SCD  sudden cardiac
eath; other abbreviations as in Table 1.emographic and Clinical Profile of LDAC Cohort
Table 2 Demographic and Clinical Profile of LDAC Cohort
Age, yrs (range) 44 16 (14–81)
Gender, men/women 22/20
Asymptomatic 12 (29%)
Symptomatic 30 (71%)
Atypical chest pain 11 (26%)
Sustained palpitation 21 (50%)
Exertional dyspnea 2 (5%)
Pre-syncope 16 (38%)
Syncope* 5 (12%)
Family history
Pathologically proven arrhythmogenic
cardiomyopathy
27 (64%)
Pathologically proven IMF 5 (12%)
Clinical diagnosis of arrhythmogenic
cardiomyopathy in relative
27 (64%)
SCD of unknown cause 18 (43%)
Proven familial disease 35 (83%; 95% CI 68%–92%)
12-lead ECG abnormalities
T-wave inversion/flattening in V5–V6  V4, I, aVL 16 (40%)
T-wave inversion/flattening in II, III, aVF 11 (27.5%)
T-wave inversion/flattening in V1–V6 3 (7.5%)
Left axis deviation (QRS axis 30°) 5 (12.5%)
Leftward QRS axis (30°  QRS axis 0) 3 (7.5%)
Early transition 2 (5%)
Left bundle branch block 1 (2%)
Late potentials on SAECG (40-Hz filter) 17/33 (51%)
Exercise testing with metabolic gas exchange
measurements (n  32)
Peak oxygen consumption, ml/kg/min 25.5  9.1
Peak oxygen consumption, (range) 84.3  20.9 (51–151)
Structural abnormalities on CMR/echocardiography†
LVEDV, % predicted (range) 127  25 (83–186)
LVEDV above upper limit of normal 24 (59%; 95% CI 42%–73%)
LVEF (%) 54  11
LVEF 55% 23 (56%)
LVEF 55% with normal LVEDV 8 (20%)
RVEDV (% predicted) 124  29
RVEDV above upper limit of normal 11 (27%; 95% CI 15%–43%)
RVEF (%) 53  7
LV wall motion abnormalities 25 (61%)
Septum 16 (39%)
Apex 21 (50%)
Inferior wall 7 (17%)
Inferolateral wall 8 (20%)
Anterolateral wall 6 (15%)
Anterior wall 3 (7%)
RV regional dilation/wall motion abnormalities 36 (86%)
Right ventricular outflow tract 30 (73%)
Subtricuspid 33 (80%)
Mid-free wall 30 (73%)
Distal free wall 9 (22%)
Apex 14 (34%)nd-diastolic volume (LVEDV) exceeding 150% of pre-
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December 16/23, 2008:2175–87 Left-Dominant Arrhythmogenic Cardiomyopathyicted, 12 had left ventricular ejection fraction (LVEF)
50%, and 2 had LVEF 35%. In comparison, the
aximum LV end-diastolic dimension determined by echo-
ardiography was 6.1 cm, whereas the lowest LVEF was
0%. Five patients (13%) had LVEF50% without marked
nlargement of LVEDV (120% predicted).
Five subjects fulfilled the Chin and Jenni criteria for
VNC (19). Two had histological evidence of fibrofatty
eplacement on endomyocardial biopsy and were found to
arry desmosomal gene mutations (Table 3). Of the remain-
ng 3 patients, 1 had a family history of pathologically
roven ARVC and 1 was Afro-Caribbean, noteworthy
ecause 13% of normal Afro-Caribbean control subjects in
recent series fulfilled criteria for noncompaction (19). The
hird suffered SCD during follow-up with post-mortem
ndings of IMF (Table 4). Affected relatives had clinical
vidence of LDAC without features of LVNC.
LV LGE was frequently present in a segment without
oincident wall motion abnormality (WMA) (76 of 107
71%] of affected segments). Circumferential LGE, extend-
ng through the outer one-third of the LV myocardium to
he right side of the septum, was apparent in 10 subjects
24%); others demonstrated a more patchy distribution
Figs. 1A and 1B). Severe LV LGE (LV lesion score  4)
ith normal LVEDV was observed in 7 patients, of whom
also had preserved global LV systolic function.
Of the 41 LDAC patients who underwent CMR, 36
88%; 95% CI: 73% to 95%) had segmental dilation and/or
MA in the RV, often localized to the triangle of dysplasia
nd mid-free wall. RV aneurysms were present in 14 (34%),
ut only 11 (27%) had RVEF below the lower limit of
ormal for age and gender. Fourteen patients (34%; 95%
I: 21% to 51%) had LV dilation and/or systolic impair-
ent with normal RV volumes and function. There was no
ignificant correlation of RV/LV volume ratio with age
Spearman r  0.08). Three patients were exceptional in
emonstrating significant RV dilation, with an RV/LV
ummary of Desmosomal Gene Changes Isolated in LDAC Cohort
Table 3 Summary of Desmosomal Gene Changes Isolated in LD
Gene Nucleotide Change Predicted Effect
DSP 3337C¡T Nonsense; premature termination (R
DSP 3045delG Frameshift; premature termination (
DSP 1325C¡T Missense (S442F)
DSP 1520C¡T Missense (S507F)
DSP 1755insA Frameshift; premature termination (
DSP 9391G¡A Mutant splice product; premature te
PKP-2 419C¡T Missense (S140F)
DSG-2 1773_1774delTG Frameshift; premature termination C
The C591X mutation in desmoglein-2 (DSG-2), S140F mutation in plakophilin-2 (PKP-2), and the
f gene identification studies (data from references [7,16,20,21]).
DSP  desmoplakin.AC Cohort
n Comment
1113X) 1 Family A
S1015fsX1017) 4 Family B
1 Family C
In highly conserved amino acid region (N-terminal)
2 Family D
In highly conserved amino acid region (N-terminal)
T586fsX594) 4 Family E
Previously published* (2034insA)
rmination 1 Family F
Previously published*
1 Previously published*
591X 1 Extracellular anchor domain
(previously published)*
desmoplakin mutations identified in families D and E have been previously reported within the contextolume ratio 1.2. All 3 had initially presented with a high
E
avents Recorded in LDAC Cohort
Table 4 Events Recorded in LDAC Cohort
63/M Background of persistent atrial fibrillation, treated with digoxin
and warfarin.
Presented with out-of-hospital VF arrest. No evidence of
digoxin toxicity.
Resting 12-lead ECG: sinus rhythm with inferolateral T-wave
inversion.
Monitoring: sinus rhythm with nonsustained VT of RBBB
morphology.
Angiogram: unobstructed coronary arteries.
CMR: mild LV dilation and systolic dysfunction (LVEF 42%),
with basal and septal midwall LGE.
ICD placement. Free from interventions at 11-month follow-up.
81/F Presented locally with pre-syncope and sustained VT of RBBB
morphology.
Resting 12-lead ECG: sinus rhythm with LBBB.
2D-echocardiogram: mild LV systolic dysfunction (LVEF 48%)
with inferior WMA.
Angiogram: unobstructed coronary arteries.
Cardiac monitoring discontinued after oral loading with
amiodarone and a 72-h arrhythmia-free interval, but
subsequently found unresponsive in bed and asystolic.
Post-mortem: heart weight 342 g; nondilated LV; thinning of
circumferential LV; fine interstitial fibrosis in lateral and
inferior walls.
51/M Presentation age 46 yrs with sustained palpitation and pre-
syncope; nonsustained VT of LV origin on exercise test and
Holter. Echocardiogram: LVEDD 5.5 cm, LVESD 4.6 cm, and
LVEF 40%. Angiographically normal coronary arteries.
Presumed diagnosis of dilated cardiomyopathy; treated
with angiotensin-converting enzyme inhibitor and beta-
blocker. Improvement noted on follow-up echocardiogram
(LVEDD 5.1 cm, LVEF 50%).
CMR showed apical, lateral, and inferolateral WMA and
extensive, patchy midwall LGE. In spite of revision of
diagnosis to LDAC, no further measures were taken owing
to prolonged symptomatic stability. Suffered SCD in his
sleep 5 yrs after first presentation. Post-mortem: diffuse
interstitial fibrosis encircling individual cardiac myocytes;
focal chronic inflammation. Diagnosis: idiopathic
myocardial fibrosis.DD  end-diastolic dimension; ESD  end-systolic dimension; other abbreviations as in Tables 1
nd 2.
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87urden of premature ventricular complexes (PVCs) of
BBB morphology, and 1 also had T-wave inversion in V4
o V6, enabling inclusion in the original study population.
MR subsequently revealed regional disease (RV WMA in
, LV WMA and RV aneurysms in the other) and LV LGE
onsistent with arrhythmogenic cardiomyopathy, allowing
ntry into the LDAC cohort. However, the combination of
eft-sided features (arrhythmia of LV origin, extensive LV
GE,  lateral T-wave inversion) with RV dilation was
ecognized to be more in keeping with the “biventricular”
ubtype of arrhythmogenic cardiomyopathy than LDAC.
xcluding these 3 individuals, the mean RV/LV volume
atio was 1 (0.97  0.15).
linical correlations. The LVEDV, expressed as a per-
entage of predicted, correlated with arrhythmia score (r 
.42, p 0.0058), but a weaker positive correlation with the
V lesion score (r  0.29) did not reach statistical signifi-
ance. There was a weak inverse correlation between LVEF
nd arrhythmia score (r  0.36, p  0.0191). Neverthe-
ess, 7 patients (17%; 95% CI: 8% to 32%) had arrhythmia
cores 3 with LVEDV 120% of predicted and LVEF
Figure 1 Patterns of Late Enhancement in LDAC
Magnetic resonance images from 2 patients in the left-dominant arrhythmogenic c
syncope and were found to have nonsustained ventricular tachycardia of left ventr
enhancement (LGE) in a midwall distribution (arrows), patchy in basal cuts (upper
circumferential LGE (lower left) and marked LV dilation with preserved right ventric
der of the cohort. Neither had symptoms of heart failure.50%. The LV lesion score showed inverse correlation with aVEF (r  0.35, p  0.0258) and stronger positive
orrelation with arrhythmia score (r  0.48, p  0.0018).
hort- and medium-term follow-up. Follow-up data were
vailable in 41 of 42 patients, with duration ranging from 1
o 60 months (mean 42 months). Three events were
ecorded (Table 4). Nine LDAC patients underwent pro-
hylactic implantable cardioverter-defibrillator placement
or syncope (n  2) and pre-syncope associated with
onsustained VT (n  6) or multiple instances of SCD in
he family (n  1). Endomyocardial biopsies were obtained at
he time of device implantation in 2 patients, 1 of whom had
reviously been diagnosed with viral myocarditis. Samples
rom the interventricular septum in both revealed loss of
yocytes with fibroadipose replacement. The histological find-
ngs were in keeping with the presence of septal LGE on CMR.
enetic profile of LDAC cohort. Results of molecular
enetic analysis in the LDAC cohort are shown in Table 3
7,16,20,21). Disease-causing mutations were identified in 8
f 24 families (15 of 33 individuals), equivalent to a pick-up
ate of 33% (95% CI: 16% to 55%). Successfully genotyped
ndividuals included the 4 who had originally presented with
yopathy (LDAC) cohort, both of whom presented in the fifth decade of life with
LV) origin. Both had unobstructed coronary arteries. The first had late gadolinium
ut becoming more confluent at mid-level (upper right). The second had near-
olumes (lower right), far exceeding the LV enlargement observed in the remain-ardiom
icular (
left) b
ular vcute chest pain and presumed viral myocarditis.
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ovel mutations in desmoplakin were identified in 2
DAC families (A to B) (Figs. 2 to 4), the sole affected
iving first-degree relative of an SCD victim with IMF
family C), and 2 affected relatives of a deceased proband
family D). In all cases, the mutations cosegregated with
linical phenotype (Table 5), with penetrance approaching
00% from late adolescence in families A to B. Absence of
he mutation was associated with normal clinical status in all
hose evaluated.
rior diagnoses in LDAC patients. The final LDAC
ohort included the 17 patients and 4 relatives with alter-
ative diagnoses at referral (DCM, HCM, mitral valve
rolapse, myocarditis/LVNC, idiopathic VT, and benign
ctopy). Among the 3 patients with presumed HCM,
nclusion of a tendon during echocardiographic measure-
ent of the septum had erroneously suggested asymmetric
eptal hypertrophy in 1; apical trabeculation had been
isinterpreted as distal HCM in another. The third had a
amily history of “cardiomyopathy” that was presumed
Figure 2 Pedigrees From Families A and B
Novel mutations in desmoplakin were identified in families A (upper panel) and B
to result in premature termination of protein translation. Genetically affected maleypertrophic and was thought to have burnt-out disease, dwing to mild LV dilation. Subsequent evaluation of her
amily was consistent with LDAC in affected members.
Frequent PVCs of RBBB morphology had been attributed
o mitral valve prolapse in another patient; contrast echocardi-
graphy and CMR demonstrated additional features of RV
MA, myocardial fat, and LV LGE, consistent with arrhyth-
ogenic cardiomyopathy. One 42-year-old woman had been
iagnosed with both myocarditis and LVNC for a triad of
hest pain, frequent PVCs, and prominent LV trabeculation
n imaging. The final diagnosis of LDAC was supported
y characteristic findings on endomyocardial biopsy and
solation of a mutation in desmoglein-2 (Table 3).
iscussion
e have previously reported early LV involvement in
amilial ARVC, supporting adoption of the broader term
arrhythmogenic cardiomyopathy,” with subclassifications
o reflect the classic right-sided, biventricular, and left-
ominant patterns of disease expression (10). Herein we
panel). Both mutations are predicted
cts (squares) and female subjects (circles) are shown as solid black.(lower
subjeescribe our experience with diagnosis and treatment of
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87DAC. Our findings highlight the interrelation of LDAC
nd ARVC within the same disease spectrum and provide a
omposite profile of this entity.
linical-genetic-pathological profile of LDAC. LDAC
ay present over a wide age range, from adolescence to age
80 years, typically with palpitation and symptoms of
mpaired consciousness. Physical examination is frequently
nremarkable. Ventricular arrhythmia of RBBB morphol-
gy is characteristic and often out of proportion to the
egree of LV dysfunction. Many patients have an additional
rrhythmic focus in the RV. A 12-lead ECG may show left
eviation of the QRS axis or inverted T waves in the
infero)lateral leads. Imaging demonstrates regional and/or
lobal LV dysfunction. A key CMR finding is LV LGE in
subepicardial/midmyocardial distribution (Fig. 4). The
V might show WMA (10), dilation, and systolic dysfunc-
ion but is affected less severely than the LV. SCD is the
ajor complication, whereas clinical heart failure is rare.
ne-third of the genotyped LDAC cohort (15 of 33
Figure 3 Histology From Proband in Family A
The proband (A1) died suddenly at age 35 years. Post-mortem examination
revealed subepicardial fibrosis extending from the inferior left ventricular wall
to the septum and lateral wall. Histology showed (A) myocytes surrounded by
fibrous tissue and sarcoplasmic vacuolization with hematoxylin and eosin stain-
ing and (B) increase in fibrous tissue (blue-green) with modified Masson’s
trichrome staining.atients from 8 of 24 families) had causative mutations in mesmosomal genes already implicated in ARVC (desmo-
lakin, plakophilin-2, and desmoglein-2), similar to the
urrent pick-up rate from genotyping in ARVC (22). The
enetic affiliation of these entities is further underscored by
heir frequent coexistence within the same family: the 11
ffected relatives excluded from the final cohort had a family
istory of LDAC/IMF but showed “classic” or “biventricu-
ar” disease patterns (10). Findings on histopathology in-
luded myocyte loss, fibrofatty replacement, and chronic
nflammatory infiltrates, again paralleling the RV changes of
RVC (23,24).
GE. LGE allows determination of the presence, location,
nd transmural extent of scarring in myocardial infarction,
n which it invariably involves the subendocardial layer
25–27). In HCM, LGE is predominantly mid-myocardial,
ccurs in hypertrophied regions, and is associated with
ncreased myocardial collagen content; its extent is linked
ith progressive disease and risk factors for SCD (28,29).
idwall LGE has also been observed in patients with
CM, in which it serves as a predictor of VT and SCD and
orresponds to macroscopic, midmyocardial fibrosis on
ost-mortem examination (30).
In ARVC, LGE originally attracted interest for tissue
haracterization of the RV, where its presence correlates
ith fibrofatty replacement on endomyocardial biopsy and
nducibility of VT during electrophysiological studies (31).
ubsequent studies have highlighted the utility of LGE in
elineating LV involvement in ARVC. The subepicardial/
idmyocardial distribution and predilection for the infe-
ior/inferolateral LV walls show close agreement with pat-
erns of fibrosis in ex vivo hearts from SCD victims and
ransplant recipients (10,14,23).
In the LDAC cohort, septal LGE was associated with
he presence of fibroadipose replacement in the 2 patients
ho underwent endomyocardial biopsy. Patchy midwall
GE in a patient who subsequently suffered SCD was
ssociated with diffuse interstitial fibrosis on post-mortem
xamination. LGE may therefore detect both interstitial
nd reparative fibrosis. A noteworthy finding in 20% of
DAC patients was circumferential LGE, resembling the
and of fibrous tissue described by pathologists in LDAC
earts (1–4). The extent of LGE showed strong correlation
ith arrhythmia score. LV LGE is commonly observed in
he absence of coincident WMA and can be extensive
ithout global LV dilation or systolic dysfunction. Both of
hese factors potentially contribute to under-detection of the
tructural abnormalities of LDAC by conventional 2D
chocardiography.
MF. In 2 probands from our cohort who suffered SCD
uring follow-up, gross autopsy findings were minimal, but
istology revealed interstitial fibrosis consistent with IMF,
ocalized to the inferior and lateral walls in 1 case, and
iffuse in the other. We are therefore able, for the first time,
o describe the in vivo counterpart of IMF. Both individuals
resented with pre-syncopal symptoms and had docu-
ented VT of RBBB morphology, with inferior T-wave
G*
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Table 5 Genotype-Phenotype Correlations in Families With Novel Mutations in Desmoplakin
Age, yrs/Gender
Family A (Pedigree, Fig. 2) (3337C¡T Mutation in DSP)
A1 35/F* Proband suffered SCD aged 35 yrs after prodrome of palpitation and pre-syncope.
Post-mortem examination: mildly depressed linear scar, approximately 2–3 mm in from the epicardium, running around the inferior wall of
the LV to the septum and extending out to the lateral wall. Histology revealed fibrosis with some fat and a few islands of surviving
myocytes (Fig. 3). The RV showed thinning and adipose replacement but no fibrosis.
A3† 72/M Asymptomatic, age 64 yrs, at initial family screening. No late potentials; normal echocardiogram.
Over next 8 years, developed late potentials on SAECG and LV dilation with mild systolic impairment (LVEDD 6.1 cm, LVEF 50%) on
echocardiography. Frequent PVCs of biventricular origin were observed on exercise testing and Holter monitoring (500/24 h).
Nine years after first evaluation, presented to local hospital with severe chest pain and diaphoresis. Troponin T raised at 0.69. Presumed
diagnosis of non–ST-segment elevation MI, but coronary arteries unobstructed on angiography. During subsequent follow-up, found to
have new ECG abnormalities, with T-wave inversion/flattening in V5 to V6 and inferiorly. CMR revealed aneurysms at the RVOT,
subtricuspid region, and mid-free wall, and extensive subepicardial and midwall LGE in the LV, sparing only the anterior wall.
A4† 37/F Palpitation and pre-syncope; T-wave inversion in V1 to V3 (dynamic and associated with symptomatic exacerbations); 1,000 ventricular
extrasystoles/24 h; RV aneurysms and LGE in inferior and inferolateral LV walls on CMR.
A5† 42/F Palpitation and pre-syncope; epsilon waves in V1 to V2; ventricular extrasystoles of LBBB and RBBB morphology on exercise testing;
CMR showed RV aneurysms and extensive LGE affecting inferior and lateral LV walls.
A17 12/M Asymptomatic. Moderate biventricular dilation on CMR.
A18 13/M Asymptomatic. RV WMA on CMR.
Family B (Pedigree, Fig. 2) (3045delG mutation in DSP)
B1 26/F* Proband suffered SCD aged 26 yrs after prodrome of palpitation and syncope. No history of dyspnea; extremely fit and active. Collapse
while playing squash; resuscitation efforts successful, but treatment withdrawn on critical care unit after she remained unresponsive off
sedation and head CT scan confirmed severe hypoxic brain damage.
Post-mortem examination: heart weight 330 g with severe LV and mild RV dilation. Myocardium appeared diffusely abnormal with pallor in
most regions, and scattered punctate areas of congestion. Histology revealed areas of necrosis, with focal infiltrates of chronic
inflammatory cells and patchy neutrophil accumulation around the necrotic myocytes. Final cause of death cited as acute cardiac failure
due to viral myocarditis.
B2† 43/F Presented locally with sustained palpitation and pre-syncope; symptoms longstanding but worsening. No signs or symptoms of heart failure.
12-lead ECG: early transition and T-wave inversion in V3 to V6. 2D-echocardiogram showed mildly dilated LV (LVEDD 5.5 cm) with moderate
systolic impairment (LVEF 30%–40%). Angiographically normal coronary arteries; preliminary diagnosis dilated cardiomyopathy. Standard
therapy with angiotensin-converting enzyme inhibitor, diuretic, and low-dose beta-blocker commenced, without symptomatic improvement.
Holter monitoring revealed15,000 multifocal PVCs/24 h, including runs of nonsustained VT.
Referred for genetic studies. Exercise testing: peak oxygen consumption 24.6 ml/kg/min (91% of predicted); multiple PVCs and nonsustained VT
of both LV and RVOT origin observed. Arrhythmic symptoms improved substantially after introduction of amiodarone. CMR revealed RV
aneurysms at subtricuspid region and mid-free wall and WMA at the outflow tract and apex. LV apex dilated and dyskinetic. Extensive LV LGE
observed in circumferential pattern (Fig. 4).
B3 19/M Asymptomatic with normal ECG, signal-averaged ECG, echocardiogram, exercise test, and Holter. CMR: RV WMA and midwall septal LGE in
2 discrete regions (Fig. 4).
B4† 41/F Presented locally aged 41 yrs with palpitation, pre-syncopal symptoms, lateral T-wave changes, and frequent, complex ventricular
arrhythmia of biventricular origin, and preserved LV function on 2D-echocardiography, initially reassured that her symptoms were benign.
Recruited for family assessment. Contrast echocardiography: heavily trabeculated LV apex that fulfilled criteria for LVNC. Nevertheless, RV
WMA at triangle of dysplasia raised suspicion of ARVC. CMR reproduced these findings and additionally demonstrated circumferential
LGE. Endomyocardial biopsy showed myocyte loss and fibroadipose replacement.
B11 Brief, infrequent episodes of palpitation. Left-axis deviation and lateral T-wave inversion on 12-lead ECG; frequent and complex arrhythmia
of both RBBB and LBBB morphology on exercise testing and Holter monitoring; multiple WMA in both ventricles with extensive near-
circumferential LV LGE (Fig. 4). Remains well on beta-blocker therapy.
Family C (1325C¡T mutation in DSP)
C1 44/M* Active, athletic proband suffered SCD at rest, apparently without premonitory symptoms. Post-mortem: septal fibrosis without ventricular
hypertrophy or dilation. IMF was diagnosis of exclusion.
C2 40/F Sister of proband. In her 20s she had 6-month cyclical flu-like illness that defied diagnosis. Manifestations included fever, diaphoresis, and
weight loss but no respiratory symptoms.
Cardiovascular evaluation: atypical chest pain and palpitation; unifocal ventricular extrasystoles and nonsustained VT with RBBB configuration and
left-axis deviation. Electrophysiology opinion: morphology considered characteristic of left posterior fascicular VT, although patient declined
formal electrophysiological studies. Beta-blockers for symptom relief were mainstay of therapy until contrast echocardiography and CMR
revealed typical RV WMA and prominent LV LGE. Amiodarone subsequently commenced with near-complete resolution of symptoms.
Family D (1520C¡T mutation in DSP)
D1 32/M* Suffered SCD after prodrome of dizzy spells and at least 1 syncopal episode. Post-mortem demonstrated arrhythmogenic cardiomyopathy
with prominent LV involvement.
D2 69/F Mother of proband. Prior syncopal episodes; current episodic palpitation.
12-lead ECG: inverted T waves in V5, V6, I, and aVL. Frequent PVCs of both LV and RVOT origin. CMR: LV mildly dilated; LVEF 43%; extensive
circumferential LGE; aneurysms at RVOT and RV subtricuspid region.
D3 47/F Sister of proband. Longstanding history of sustained palpitation at rest (often nocturnal).
12-lead ECG: leftward QRS axis; equivocal R-wave progression; flattened T waves in I, V5 to V6, and inferior leads. Exercise testing: peak
oxygen consumption 30.2 ml/kg/min (117% of predicted); multiple PVCs and nonsustained VT of predominantly LV origin observed.
CMR revealed localized dilation and WMA at RVOT and subtricuspid region, with extensive LV LGE including septum.Deceased. †Implantable cardioverter-defibrillator placement.
MI  myocardial infarction; LVEDD  left ventricular end-diastolic diameter LVNC  left ventricular non-compaction; RVOT  right ventricular outflow tract; other abbreviations as in Tables 1 and 2.
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87nversion or left bundle branch block (LBBB) on resting
CG (Table 4). One patient underwent antemortem CMR
xamination, which revealed extensive patchy midwall LV
GE. Two of his relatives presented independently and
howed similar findings.
The clinical profile of IMF therefore overlaps with that of
DAC. Clinical features of ARVC were also observed in 2
amilies who had lost a first-degree relative to IMF; a
esmoplakin mutation was subsequently identified in 1
C2), suggesting that IMF might be a clinical manifestation
f arrhythmogenic cardiomyopathy. A major distinction
etween the 2 entities has hitherto been the presence of
yocardial fat in arrhythmogenic cardiomyopathy. Experi-
nce with Carvajal syndrome, however, suggests that fat is
ot a requisite feature in all forms of arrhythmogenic
ardiomyopathy. Carvajal syndrome was originally de-
cribed as a triad of palmoplantar keratoderma, woolly hair,
nd DCM secondary to a homozygous mutation in desmo-
lakin (32). Detailed pathological examination of the heart
rom a Carvajal patient demonstrated myocardial loss and
eplacement fibrosis in the subepicardial layers, and aneu-
ysms in both the LV and RV triangle of dysplasia. Clinical
ndings include precordial T-wave inversion and early
rrhythmogenicity; the subsequent prevalence of heart fail-
re is a probable corollary of the homozygous mutation,
ith the gene-dose effect causing rapid progression to end
tage disease. Despite the absence of adipose replacement,
he phenotype is more typical of arrhythmogenic cardiomy-
Figure 4 Magnetic Resonance Images From Family B
Late gadolinium enhancement (LGE) in 3 members of family B: B11 (top left), B2
midwall LGE (arrows), which tracks around in a near-circumferential pattern. In B2
one-third of the myocardium and the right side of the interventricular septum. In B
the left-hand 4-chamber view, 1 of which is reproduced in the short-axis cut on the
affected relatives had the 3045delG mutation in desmoplakin.pathy than DCM (32). Fibrofatty replacement likely rep- pesents a nonspecific reparative process; why adipose tissue
redominates in some patients while others manifest only
brosis remains unclear.
Also unresolved is the predominance of interstitial fibro-
is, as opposed to replacement fibrosis, in some cases of IMF
13). Whereas replacement fibrosis is a repair mechanism
fter cell loss, interstitial fibrosis is a reactive process that
ccurs in the absence of myocyte necrosis, in response to
riggers as disparate as ventricular hypertrophy, radiation,
nd ischemia. Both forms of fibrosis have been observed in
RVC (23).
he role of myocarditis. It has recently been suggested
hat the LDAC phenotype is the result of chronic myocar-
itis (33), with or without underlying ARVC. Several lines
f evidence seem to support this premise. First, almost
ne-third of the cohort reported recurrent chest pain.
econd, 4 patients had a prior diagnosis of myocarditis
presumed viral) on the basis of an episode of acute chest
ain in the setting of angiographically normal coronary
rteries. Third, both subepicardial and midwall LGE have
een reported in patients fulfilling Dallas criteria for myo-
arditis on endomyocardial biopsy (34) and among individ-
als with chest pain, Troponin rise, and unobstructed
oronary arteries (35). Familial evaluation was not con-
ucted in either population.
In contrast, our study was distinguished by active inves-
igation for familial disease, which was proven in 83% and
uspected in a further 12% owing to a family history of
ight), and B3 (lower panels). In B11 (top left), the septum shows prominent
ight), subepicardial LGE (arrows) is seen as a circumferential band in the outer
er panels), 2 areas of midwall LGE (arrows) are discernible in the septum on
. B3 was distinguished by an otherwise normal cardiovascular evaluation. All(top r
(top r
3 (low
rightremature SCD. Furthermore, 38% of genotyped patients
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December 16/23, 2008:2175–87 Left-Dominant Arrhythmogenic Cardiomyopathyn the LDAC cohort had mutations in desmosomal genes,
trengthening the view that LDAC is an inherited, genet-
cally determined disorder.
The apparently conflicting findings are best reconciled by
ostulating that inflammatory myocarditis is part of the
atural history of arrhythmogenic cardiomyopathy, where it
as a genetic rather than an infective basis. Focal lympho-
yte infiltrates and myocyte necrosis consistent with myo-
arditis occur in up to 67% of ARVC hearts on post-
ortem examination (24), lending further support to this
remise. Bauce et al. (8) described clinical presentation with
yocarditis in 2 siblings with familial arrhythmogenic
ardiomyopathy secondary to a mutation in desmoplakin.
oth had chest pain, ST-segment elevation, and myocardial
nzyme release in the setting of angiographically normal
oronary arteries.
The desmosomal model of arrhythmogenic cardiomyop-
thy offers an explanation at a molecular level (9,22).
esmosomes are specialized intercellular junctions that
nchor intermediate filaments to the cytoplasmic membrane
n adjacent cells, imparting mechanical strength via both
ell–cell adhesion and transmission of force between the
unctional complex and the cytoskeleton. Mutations in
esmosomal genes may compromise either intercellular
dhesion or intermediate filament function or both, depend-
ng on their impact on protein structure and function.
onsequent myocyte loss may be accompanied by an in-
ammatory response and is followed by repair with fibrous
r fibrofatty tissue. Rather than being a continuous process,
isease progression is purported to occur during occa-
ional “hot phases” (22), when an unknown stimulus
ctivates cell loss and inflammation in a previously
uiescent region of the myocardium. Therefore a propor-
ion of adults with chest pain, unobstructed coronary
rteries, and apparent myocarditis might have underlying
rrhythmogenic cardiomyopathy.
Activation of the disease process might also result in
ransient electrical instability and rarely SCD. Should death
ccur during an early “hot phase,” post-mortem examina-
ion of the heart might show myocyte necrosis and inflam-
atory infiltrates in lieu of the characteristic fibrofatty
eplacement, as in case B1 (Table 5) and as previously
escribed by Bauce et al. (8).
DAC versus ARVC with LV involvement. LV involve-
ent in the advanced stages of ARVC is well recognized
8,23). In light of the high prevalence of RV abnormalities,
t is tempting to ascribe the LDAC phenotype to normal
isease progression. There are, however, several counters to
his premise. First, over 75% of LDAC patients had
entricular arrhythmia of RBBB morphology, although just
ver one-half had an additional LBBB-type focus. “Classic”
RVC is characterized by ventricular arrhythmia of LBBB
orphology, as outlined in the task force criteria for ARVC;
ultifocal arrhythmia is less frequently reported, and pure
V arrhythmia occurs very seldom. Second, the most
ommon ECG finding was T-wave inversion confined to lhe (infero)lateral leads; gradual extension to the right
recordial leads was documented in 2 patients, in apparent
eversal of the pattern of progression observed in “classic”
RVC. Third, the septum is generally spared even in
ate-stage ARVC with LV involvement. In contrast, 50%
f the clinical LDAC cohort had septal LGE. Fourth,
solated global RV dysfunction precedes LV involvement in
he classic pattern of disease expression (10). In the LDAC
ohort, however,30% had LV dilation and/or impairment
n the presence of preserved right-sided volumes and
unction.
“Classic” ARVC is characterized by RV preponderance
hroughout the disease course; the RV/LV volume ratio
hows positive correlation with age and is typically 1.4
mong individuals with advanced disease and LV involve-
ent. The “biventricular” pattern is defined by parallel
nvolvement of both ventricles, with the volume ratio
emaining approximately 1 throughout the disease course.
rue LDAC is purported to mirror the “classic” pattern,
ith the LV consistently more severely affected than the
V. The RV/LV volume ratio is typically1 in LDAC and
s expected to correlate inversely with age. In both our
arlier series and the present cohort, this inverse correlation
as weak and failed to reach statistical significance (10).
he reasons for this are 2-fold. First, the protocol of the
urrent study employed arrhythmia of LV origin and (in-
ero)lateral T-wave inversion as primary inclusion criteria:
oth key features of LDAC but also recognized in the
biventricular” subtype of arrhythmogenic cardiomyopathy.
he corollary is a cohort that highlights the profile of
onclassic arrhythmogenic cardiomyopathy and its common
isattribution to other disorders but might not wholly
epresent pure LDAC. Second, extensive LV LGE might
recede the onset of global LV systolic dilation, limiting the
tility of the RV/LV volume ratio as an indicator of early
eft-dominant disease and precluding its use in ascertain-
ent of the cohort. In some cases, distinction between
he left-dominant and biventricular patterns might not be
ossible until ventricular dilation ensues with disease
rogression.
DAC versus DCM. Differentiating the LDAC pheno-
ype from DCM is clinically important to guide risk
tratification and familial evaluation. Regional disease in-
olvement is suggestive of arrhythmogenic cardiomyopathy,
articularly when RV abnormalities are prominent;
neurysms are almost pathognomonic. The pattern of
GE might be a further aid to diagnosis; mid-wall en-
ancement is observed in both LDAC and DCM, but
ubepicardial distribution raises suspicion of arrhythmo-
enic cardiomyopathy.
One of the defining characteristics of arrhythmogenic
ardiomyopathy, and the principal means of distinction
rom DCM, is a predisposition to ventricular arrhythmia
hat exceeds the degree of morphological abnormality and
ystolic impairment. While frequent and complex ventricu-
ar arrhythmia is a recognized feature of DCM, and SCD
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Left-Dominant Arrhythmogenic Cardiomyopathy December 16/23, 2008:2175–87ccounts for at least 30% of the overall mortality, both occur
n the context of overt systolic dysfunction. Furthermore,
lthough a significant proportion of individuals with DCM
ompensate at New York Heart Association functional class
or II, heart failure is the primary mode of presentation. In
ontrast, among LDAC patients with clinically significant
entricular arrhythmia (grade 2), the mean LVEF on
MR was 54  11%. Events in the LDAC population,
ncluding both the clinical cohort and deceased index cases,
ccurred in apparently fit individuals; premonitory symp-
oms, if any, were palpitation and syncope. None had signs
r symptoms of clinical heart failure, although a proportion
f patients with arrhythmogenic cardiomyopathy may de-
elop this complication late in the disease course. Arrhyth-
ic control and prevention of SCD are therefore the
oremost goals of therapy in LDAC; relatively preserved LV
ystolic function may belie significant risk of events.
tudy limitations. Key limitations include referral bias due
o recruitment of study patients from a tertiary center
nherited Cardiovascular Disease service. Furthermore, the
ase-mix was skewed by a paucity of index cases requiring
valuation for arrhythmia and a preponderance of relatives
ndergoing familial evaluation, reflecting the special inter-
sts of our center. Although its capacity to mimic other
iseases might contribute to under-recognition, the true
revalence of LDAC remains unclear, pending systematic
valuation of patients with unexplained arrhythmia and
CG changes of LV origin in large, community-based
opulations.
onclusions
e are able to summarize the salient clinical features of
DAC (Table 6) for incorporation into forthcoming revi-
ions of the Task Force criteria, to facilitate diagnosis of
eft-dominant and biventricular disease variants. It should
e emphasized that the unified conception of LDAC/IMF
resented here is based predominantly on similarities in
linical profile. As in HCM and DCM, there is consider-
ble phenotypic heterogeneity, incorporating fibrofatty and
ure fibrotic forms. Both may occur in conjunction with
esmosomal mutations, strengthening the premise that
esmosomal dysfunction is the final common pathway.
evertheless, molecular classification on this basis might be
linical Diagnostic Features of LDAC*
Table 6 Clinical Diagnostic Features of LDAC*
ECG Unexplained T-wave inversion in V5, V6  V4, I, and
Arrhythmia Sustained or nonsustained ventricular tachycardia o
Frequent ventricular extrasystoles (RBBB morpholog
Imaging LV aneurysms
Mild LV dilation and/or systolic impairment (with ar
Biopsy/CMR Myocyte loss with fibrofatty replacement on histolog
Extensive LGE of LV myocardium (with subepicardia
The distinction from dilated cardiomyopathy is made on clinical grounds, as discussed earlier.
Abbreviations as in Table 1.remature. The success rate from screening the knownesmosomal genes in the LDAC cohort was approximately
0%, similar to that in unselected ARVC populations (22).
ccepting that a significant proportion of the remainder
ight have mutations in other components of the desmo-
ome, this is still unlikely to wholly account for the
iscrepancy, and extra-desmosomal genes will likely have to
e sought. Transmembrane protein 43 has recently been
mplicated in ARVD5, which is associated with early and
rominent LV involvement (36). The transmembrane pro-
ein 43 gene contains a response element for peroxisome
roliferator-activated receptor-gamma, an adipogenic tran-
cription factor that is also involved in epithelial cell
ifferentiation; at this juncture, however, an association with
esmosomal development and function remains speculative.
urther mechanistic insight into the broad spectrum of
rrhythmogenic cardiomyopathy awaits fresh gene identifi-
ation and expression studies with phenotypic correlation.
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